Takeda moves away from AAV gene therapy in rare hematology April 06, 2023 - Takeda is moving away from early-stage R&D work in adeno-associated virus-based gene therapies and the rare hematology spaces - which follows the lead of other Big Pharma companies who similarly withdrew from gene therapy work for the treatment of cancers. These discontinuations could work to benefit ONCY over the medium-long run.
https://www.fiercebiotech.com/biotech/layoffs-loom-takeda-trims-early-stage-efforts-aav-gene-therapy-rare-hematology
Takeda's December 2019 news release:
https://www.takeda.com/en-us/newsroom/news-releases/2019/takeda-demonstrates-its-commitment-for-rare-bleeding-disorders-at-ash-2019